Literature DB >> 18404390

Drugs and prolactin.

Mark E Molitch1.   

Abstract

Medications commonly cause hyperprolactinemia and their use must be differentiated from pathologic causes. The most common medications to cause hyperprolactinemia are the antipsychotic agents, although some of the newer atypical antipsychotics do not do so. Other medications causing hyperprolactinemia include antidepressants, antihypertensive agents, and drugs which increase bowel motility. Often, the medication-induced hyperprolactinemia is symptomatic, causing galactorrhea, menstrual disturbance, and erectile dysfunction. In the individual patient, it is important differentiate hyperprolactinemia due to a medication from a structural lesion in the hypothalamic-pituitary area. This can be done by stopping the medication temporarily to determine if the prolactin (PRL) levels return to normal, switching to another medication in the same class which does not cause hyperprolactinemia (in consultation with the patient's physician and/or psychiatrist), or by performing an MRI or CT scan. If the hyperprolactinemia is symptomatic, management strategies include switching to an alternative medication which does not cause hyperprolactinemia, using estrogen/testosterone replacement, or cautiously adding a dopamine agonist.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404390     DOI: 10.1007/s11102-008-0106-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  131 in total

1.  The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.

Authors:  A M Crawford; C M Beasley; G D Tollefson
Journal:  Schizophr Res       Date:  1997-07-25       Impact factor: 4.939

2.  Hyperprolactinaemia during famotidine therapy.

Authors:  G Delpre; M Lapidot; A Lipchitz; E Livni; U Kadish
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

3.  Hyperprolactinemia-galactorrhea induced by verapamil.

Authors:  E L Fearrington; C H Rand; J D Rose
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

4.  Plasma-prolactin and cimetidine.

Authors:  M Petrillo; A Prada; G B Porro; M Bevilacqua; V Raggi; G Norbiato
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321

5.  Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment.

Authors:  J B Cohn; J Brust; F DiSerio; J Singer
Journal:  Neuropsychobiology       Date:  1985       Impact factor: 2.328

6.  Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects.

Authors:  Gavin Bart; Lisa Borg; James H Schluger; Mark Green; Ann Ho; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2003-05-02       Impact factor: 4.030

7.  Growth and sexual maturation during long-term treatment with risperidone.

Authors:  Fiona Dunbar; Vivek Kusumakar; Denis Daneman; Miklos Schulz
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

8.  Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women.

Authors:  P L Hwang; C S Ng; S T Cheong
Journal:  Clin Endocrinol (Oxf)       Date:  1986-02       Impact factor: 3.478

9.  Effects of trazodone treatment on serotonergic function in depressed patients.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychiatry Res       Date:  1988-05       Impact factor: 3.222

10.  Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.

Authors:  R Keller; F Mongini
Journal:  Neurol Sci       Date:  2002-12       Impact factor: 3.307

View more
  18 in total

Review 1.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Endocrine abnormalities in cardiofaciocutaneous syndrome: a case of precocious puberty, hyperprolactinemia and diabetes insipidus.

Authors:  Stephanie Lenet; Constantin Polychronakos
Journal:  BMJ Case Rep       Date:  2019-06-18

3.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

5.  Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.

Authors:  Prasad Dandawate; Gaurav Kaushik; Chandrayee Ghosh; David Standing; Afreen Asif Ali Sayed; Sonali Choudhury; Dharmalingam Subramaniam; Ann Manzardo; Tuhina Banerjee; Santimukul Santra; Prabhu Ramamoorthy; Merlin Butler; Subhash B Padhye; Joaquina Baranda; Anup Kasi; Weijing Sun; Ossama Tawfik; Domenico Coppola; Mokenge Malafa; Shahid Umar; Michael J Soares; Subhrajit Saha; Scott J Weir; Animesh Dhar; Roy A Jensen; Sufi Mary Thomas; Shrikant Anant
Journal:  Gastroenterology       Date:  2019-11-29       Impact factor: 22.682

6.  Evaluation of serum prolactin levels in intellectually disabled patients using antipsychotic medications.

Authors:  Tammy L Lambert; Kevin C Farmer; Nancy C Brahm
Journal:  Int J Endocrinol Metab       Date:  2012-12-21

7.  Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study.

Authors:  Sollip Kim; Young-Min Park
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

8.  Baseline serum concentrations of zinc, selenium, and prolactin in critically ill children.

Authors:  Sabrina M Heidemann; Richard Holubkov; Kathleen L Meert; J Michael Dean; John Berger; Michael Bell; K J S Anand; Jerry Zimmerman; Christopher J L Newth; Rick Harrison; Douglas F Willson; Carol Nicholson; Joseph Carcillo
Journal:  Pediatr Crit Care Med       Date:  2013-05       Impact factor: 3.624

9.  Drug-induced Hyperprolactinemia Results in Atypical Atypical Fracture.

Authors:  Ingyu Lee; Dong-Wook Son; Jun Hyoung Park; Jai Hyung Park
Journal:  Hip Pelvis       Date:  2021-06-04

10.  Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors:  Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring
Journal:  BMC Endocr Disord       Date:  2013-03-21       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.